Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 26, 2025 07:00 ET | Source: Arvinas Inc.

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
November 25, 2025 08:20 ET | Source: SNS Insider pvt ltd

Targeted Protein Degradation Market Size Worth USD 2216.13 Million by 2032 Fueled by the Potential to Treat "Undruggable" Diseases – SNS Insider

Austin, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Targeted Protein Degradation Market Size & Growth Analysis: According to SNS Insider, the global Targeted Protein Degradation Market was valued at USD...
November 24, 2025 07:00 ET | Source: Arvinas Inc.

Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)

NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
November 05, 2025 07:00 ET | Source: Arvinas Inc.

Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

– Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson’s disease – – Presented preclinical data from ARV-806 demonstrating robust and...
November 03, 2025 16:00 ET | Source: Arvinas Inc.

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
November 03, 2025 07:00 ET | Source: Arvinas Inc.

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
October 29, 2025 07:00 ET | Source: Arvinas Inc.

Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025

NEW HAVEN, Conn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
October 24, 2025 16:00 ET | Source: Arvinas Inc.

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

– In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in models of pancreatic, colorectal, and lung cancer – – Data underscore...
October 22, 2025 16:00 ET | Source: Arvinas Inc.

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

NEW HAVEN, Conn., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
October 20, 2025 04:15 ET | Source: Arvinas Inc.

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

– Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including...